Luminex has started clinical and analytical trials to assess its Aries Group B Streptococcus (GBS) assay.
The studies for the assay are being carried out at various clinical laboratories in the US.
Based on these results, the company plans to submit application with FDA for the ARIES platform approval, while for Aries HSV 1&2 Assay is expected to occur in the summer of this year.
Luminex president and CEO Homi Shamir said: "We continue to build momentum in our commercial launch schedule for the Aries platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline.
"The progression of our Aries menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."
Aries is a sample to answer system, which uses internal barcode scanning and other advanced features to reduce operator errors.
Allowing for STAT and Batch testing, two independent magazine modules support from one to six cassettes each, while simultaneous IVD and laboratory developed tests (LDTs) operate through a common universal assay protocol.
Image: Luminex’s Aries system. Photo: courtesy of Luminex Corporation.